IngredientsSerratiopeptidase (Serratia E-15 protease, also known as serralysin, serrapeptase, serratiapeptase, serratia peptidase, serratio peptidase, or serrapeptidase) is a proteolytic enzyme (protease) produced by enterobacterium Serratia sp. The enzyme has an EC number 3.4.24.40 and belongs to the group Serralysin.
Serratiopeptidase is a zinc-containing metalloprotease of molecular weight 45–60 kDa. More precisely, serrapeptase is an extracellular metalloendopeptidase composed of 470 amino acids, with a molecular weight of approximately 50,000 Da. The active site of the enzyme, which contains a zinc atom, hydrolyzes nonterminal peptide linkages of polypeptides. The enzyme was characterized to be free of any sulfur-containing amino acids such as cysteine and methionine. It belongs to the serralysin group of enzymes (EC number 3.4.24.40) and is known to cleave peptides with linkages of Asn-Gln, CysSO₃H-Gly, Arg-Gly, and Tyr-Tyr, as well as the bond between His-Leu, Gly-Ala, Ala-Leu, Tyr-Leu, Gly-Gly, Phe-Tyr, and Tyr-Thr, showing broad substrate specificity.
Serratiopeptidase showed maximum activity at pH 9 and 40°C, and can be inactivated at 55°C for 15 minutes. Serralysin contains one atom of zinc per molecule as an essential element, indicating that the serralysin family belongs to the metzincin class of proteases according to the MEROPS database.
The organism was originally isolated in the late 1960s from silkworm (Bombyx mori L.) intestine. Serratiopeptidase is present in the silkworm intestine and allows the emerging moth to dissolve its cocoon. Serratiopeptidase is an alkaline metallopeptidase originally isolated from Serratia marcescens; later, homologs of this enzyme were also reported from some genera of gram-negative and positive bacteria, such as Pseudomonas aeruginosa, Proteus mirabilis, Erwinia chrysanthemi, Xenorhabdus, Deinococcus radiodurans, and Bacillus subtilis.
The enzyme has a molecular size of 52 kDa and has the ability to bind with alpha-2-macroglobulin in blood at a ratio of 1:1. Since alpha-2-macroglobulin in the human bloodstream has high affinity for zinc, serratiopeptidase is able to bind to alpha-2-macroglobulin via its active site in a molar ratio of 1:1; therefore, it is transferred to the sites of inflammation, meanwhile retaining its biological activity.
Maximal proteolytic activity occurs at 40°C and at a pH of approximately 8 (range, 6 to 10). Maintaining the temperature at 55°C for 15 minutes inactivates the enzyme. Serrapeptase is manufactured by fermentation technology in which the enzyme is purified from bacterial culture. Serratiopeptidase, a metalloprotease produced by Serratia marcescens, is produced through a fermentation process using carbohydrates and proteins as carbon and nitrogen sources.
Serratiopeptidase is commonly available in enteric-coated tablets and capsules to protect the enzyme from gastric degradation, ensuring systemic absorption in the intestine. Being sensitive to gastric degradation, serratiopeptidase is conventionally given orally in the form of enteric-coated tablet formulations. This enteric coating consists of pH-sensitive polymers which remain intact at gastric acidic pH (1.5–3.5) and solubilize in the more favorable alkaline pH (6.5–7.6) of the small intestines. In order to increase the stability of serratiopeptidase (reduced acid hydrolysis) and improve oral bioavailability simultaneously, several techniques have been explored, including delivery entrapped in Eudragit S100 microspheres, liposomal formulations, alginate gel encapsulation, chitosan-coated ceramic nanocores, in situ cubic phase transforming systems, and polar lipid-based lipospheres.
Topical formulations of serratiopeptidase have also been explored to treat local inflammations and may prove more effective than non-steroidal anti-inflammatory agents for localized conditions.
This microorganism was originally isolated in the late 1960s from silkworm Bombyx mori L. Serratiopeptidase is present in the silkworm intestine and allows the emerging moth to dissolve its cocoon. Its anti-inflammatory property was first studied in Japan in 1967. Later, during the 1970s, these parenteral enzyme preparations were replaced by oral enteric-coated tablet form.
First approved for therapeutic use in Japan in 1968, serratiopeptidase was employed as a pharmaceutical agent primarily for its anti-inflammatory, analgesic, anti-edemic, and mucolytic properties, helping to break down proteins, reduce swelling, and alleviate pain by hydrolyzing bradykinin, histamine, and serotonin.
During the 1980s and 1990s, it was proposed by separate research conducted in Europe and Japan that serratiopeptidase was the most effective agent in reducing inflammation among all other enzyme preparations. Serratiopeptidase has been used for almost 40 years in Japan and Europe for pain and inflammation due to arthritis, trauma, surgery, sinusitis, bronchitis, carpal tunnel syndrome, and painful swelling of breasts.
During the 1980s and 1990s, research conducted separately in Europe and Japan demonstrated that serratiopeptidase was the most effective agent in diminishing inflammation among all available enzyme formulations. It subsequently came to be broadly used in Japan and Europe as an anti-inflammatory and analgesic agent of choice.
Takeda Pharmaceutical halted sales of the anti-inflammatory enzyme preparation Dasen (serrapeptase) in Japan after it decided not to conduct the additional clinical trials required for its continued marketing. Specifically, Japan's largest drugmaker, Takeda Pharmaceutical, voluntarily recalled Dasen (serrapeptase) 5 mg and 10 mg tablets, and 1% granules, its anti-inflammatory enzyme preparations sold in Japan. In the double-blind studies that were conducted to compare Dasen with placebo, no statistically significant differences were found.
In Japan, the proprietor Takeda voluntarily withdrew serratiopeptidase in 2011; thereafter, the Singapore government decided to phase out serratiopeptidase-containing preparations as medicinal products due to some controversial results of the trials and lack of substantive scientific evidence. Serratiopeptidase has been restricted or banned in several countries, including the United Kingdom, where it is deemed an unauthorized novel food under EU Regulation 2015/2283 due to insufficient historical consumption evidence and unproven health claims, prohibiting its sale as a supplement without prior safety authorization.
Serratiopeptidase has been approved in Canada for use as an ingredient in dietary supplements to reduce pain and swelling. In India, it is approved as a pharmaceutical ingredient for the treatment of acute pain in combination with other drugs. In India, serratiopeptidase holds approval by the Central Drugs Standard Control Organization as an active pharmaceutical ingredient specifically for the treatment of acute pain, often in combination with other analgesics or anti-inflammatory drugs, targeting conditions involving inflammation and swelling such as postoperative wounds. In the United States, serratiopeptidase is classified as a dietary supplement ingredient subject to New Dietary Ingredient (NDI) notification requirements under the Federal Food, Drug, and Cosmetic Act.
Serratiopeptidase is a metalloprotease and contains zinc and calcium ions as ligands along with a single active site. The zinc ion is important for the enzyme and enhances its proteolytic activity. The purified enzyme shows a molecular weight of approximately 50 kDa with a purity above 96%, an isoelectric point of approximately 4.6, and optimal pH and temperature of 6 and 50°C.
Presently, serratiopeptidase obtained from Serratia E-15, classified as an opportunistic pathogen, is used in therapy for inflammation; due to its pathogenicity, the enzyme has been reported to cause lung and corneal damage. This pathogenicity concern has driven considerable research into producing the enzyme through recombinant expression in non-pathogenic hosts such as Escherichia coli. The evolution of Serratia marcescens as an opportunistic pathogen associated with various infections has led researchers to develop an alternate strategy for its industrial production, including successful cloning, expression, and purification of active serratiopeptidase using Escherichia coli BL21 [DE3].
Serratiopeptidase is a proteolytic enzyme with immense applications in therapeutic areas, validated by several in vitro, in vivo, and clinical studies as well as through anecdotal evidence. These applications are attributable to its versatile properties including anti-inflammatory, anti-biofilm, analgesic, anti-edemic, and fibrinolytic effects.
Serratiopeptidase exerts its effects primarily through the selective degradation of non-living proteins and inflammatory mediators, distinguishing it from living tissue. As a zinc metalloprotease belonging to the serralysin family (EC 3.4.24.40), its catalytic domain enables the hydrolysis of specific peptide bonds in substrates such as Arg-Gly and Tyr-Leu, facilitating targeted proteolysis without harming viable cells. This structural feature allows the enzyme to break down denatured proteins like fibrin, bradykinin, and amyloid fibrils, which accumulate during pathological processes. The enzyme's anti-inflammatory action involves the proteolytic degradation of key mediators such as bradykinin, a peptide that promotes pain and edema by increasing vascular permeability. By cleaving bradykinin and other kinins, serratiopeptidase reduces local inflammation and associated swelling.
The anti-inflammatory and analgesic activity of serratiopeptidase is achieved by degrading the inflammation-causing amino acid derivatives such as histamine, serotonin, and bradykinin.
Serratiopeptidase has the ability to bind with cyclooxygenase and suppress the release of interleukins and prostaglandins. The enzyme has its mode of action on the arachidonic acid pathway (COX I and COX II) and acts on the cyclooxygenase pathway, but not on the lipoxygenase pathway (LOX). Serratiopeptidase has a strong affinity for cyclooxygenase (COX) I and II, which are crucially linked with interleukin (IL), prostaglandin (PGs), and thromboxane (TXs) production.
Serratiopeptidase breaks down fibrin, thins the fluids formed during inflammation, and acts as an anti-biofilm agent. Clinical studies have shown that it can digest dead tissues, blood clots, cysts, and arterial plaques. The fibrinolytic property is believed to contribute to the enzyme's utility in conditions where fibrin accumulation contributes to chronicity and restricted blood flow, though the anti-atherosclerotic data in humans remain largely anecdotal (see Section 6).
Another key mechanism is the enzyme's ability to thin mucus. In conditions like chronic sinusitis or bronchitis, mucus can become thick and difficult to expel. Serrapeptase helps by breaking down the protein structure of the mucus, thereby making it less viscous and easier to clear from the body. The enzyme reduces exudate viscosity and inhibits hydrolysis of inflammatory mediators such as histamine, bradykinin, and serotonin.
Serratiopeptidase acts as an agent against biofilms — multicellular structures of dense and highly hydrated communities of microorganisms embedded in a matrix of self-synthesized polymeric or proteinaceous material. As an accessible bacterial metalloproteinase, it has proven effective against various biofilm-associated diseases: it can alter the virulence phenotype of bacteria in biofilms, is effective against mature biofilms, and enhances the bactericidal effect of antibiotics against bacterial biofilms. New knowledge calls attention to a novel mechanism of action of serratiopeptidase. This protein could be developed as a potential "antipathogenic agent" capable of impairing the ability of S. aureus to form biofilm on prostheses, catheters, and medical devices, exploiting a mechanism different from its proteolytic activity.
Serratiopeptidase is distributed to the tissues and bioavailable in plasma and lymph following binding to alpha-2-macroglobulin in the blood, thus devoid of allergenicity, and retains its enzymatic activity at the systemic and cellular level within 1 hour. Serratiopeptidase was also detected in carrageenan-induced inflammatory tissue in animals at concentrations higher than that in plasma. It was concluded in the study that serratiopeptidase is absorbed from the intestine and distributed to the inflammatory site via blood or lymph.
Orally administered serratiopeptidase is absorbed from the intestinal tract and reaches circulation in an enzymatically active form. In rat blood it exists as a complex with plasma protease inhibitor alpha-1 macroglobulin (α1M) with a molar binding ratio of 1:1, which helps to mask its antigenicity but still retains 20% of its original caseinolytic activity. However, pharmacokinetic data including its oral bioavailability in humans is not mentioned anywhere, nor is the specific concentration required for its therapeutic action.
The most common problem associated with serratiopeptidase oral delivery is the high risk of enzymatic degradation in the gastrointestinal tract due to its proteinaceous nature. In addition, the hydrophilic nature of serratiopeptidase leads to low intestinal membrane permeability, due to which a very high dosage needs to be orally administered to elicit significant anti-inflammatory responses.
Serratiopeptidase has been used in surgery (traumatic and postoperative inflammation, venous inflammatory disease, cystitis, epididymitis), orthopedics (traumatic swelling after sports injury, carpal tunnel syndrome, osteoarticular infection to increase antibiotic concentration at infection site), otolaryngology (sinusitis, rhinitis, laryngitis, bronchitis, inadequate expectoration of sputum in bronchial asthma), gynecology (engorgement of breasts), and dentistry (anti-inflammatory use and to increase antibiotic concentration at site of infection in periodontitis, pericoronitis of wisdom tooth).
The evidence from clinical studies has been graded according to the checklist given by the Scottish Intercollegiate Guidelines Network (SIGN). The grading showed that the studies supporting the anti-inflammatory and analgesic role of serratiopeptidase are generally of poor methodology. The RCTs were only a few in number (14 RCTs in total excluding duplicated studies). They had a limited population, not more than 150 patients per group in any of the studies, and were of short duration. The evidence supporting the use of serratiopeptidase as an anti-inflammatory and analgesic agent is based on clinical studies of poor methodology. Only a few RCTs, which are usually placebo-controlled with a small sample size, exist. The dose and duration of treatment were not specified in some studies, and the outcome of the study was not clearly defined in a few. Data on the safety and tolerability of serratiopeptidase is lacking in these studies.
In a 2021 RCT involving patients undergoing impacted third molar surgery, serratiopeptidase administration (10 mg three times daily for 7 days) significantly improved trismus and reduced facial swelling compared to placebo, with measurable decreases in mouth opening limitation and edema volume on days 3 and 7 post-surgery. A 2023 systematic review and meta-analysis of six RCTs on third molar extractions confirmed that serratiopeptidase reduces trismus but showed no significant impact on pain or inflammation reduction overall.
Trypsin–chymotrypsin and serratiopeptidase demonstrated statistically comparable postoperative pain reduction to ibuprofen. Trypsin–chymotrypsin and serratiopeptidase exhibit comparable efficacy to nonsteroidal anti-inflammatory drugs, i.e., ibuprofen. Most clinical studies are of limited quality and many lack adequate blinding or randomization. Study limitations include the single-center design, the short follow-up period limited to early postoperative outcomes, and the absence of objective biomarkers of inflammation, relying instead on clinical parameters.
A 1990 multicenter, double-blind, randomized, placebo-controlled trial evaluated serratiopeptidase in 193 patients with acute or chronic otorhinolaryngological inflammation, including nasal and throat disorders, using a treatment duration of 7–8 days. Additionally, a 1984 multicenter, double-blind, placebo-controlled trial in 174 patients undergoing maxillary sinus antrotomy surgery demonstrated that serratiopeptidase (10 mg three times daily for a total of 7 days) significantly reduced postoperative buccal swelling. Clinical evidence for serratiopeptidase in sinusitis and related otorhinolaryngological (ENT) conditions remains limited, with no large-scale or recent trials specifically targeting sinusitis identified.
A 2003 open-label study in patients with chronic airway disease showed that serratiopeptidase (30 mg daily for 4 weeks) reduced sputum viscosity, elasticity, and neutrophil count, potentially relevant to mucus-related symptoms in chronic sinusitis. The mucolytic evidence is considered preliminary given the open-label design and lack of subsequent large, controlled trials in the literature.
A 2024 RCT on ankle sprain cases found serratiopeptidase (5 mg three times daily for 10 days) more effective than paracetamol in reducing joint edema, with statistically significant improvements in swelling measurements. It was concluded that serratiopeptidase had good activity against pain and acute inflammation, and for the first time, it was demonstrated that serratiopeptidase ameliorated and prevented hyperthermia.
Serratiopeptidase has been used for treatment of carpal tunnel syndrome. A preliminary clinical trial of serratiopeptidase in patients with carpal tunnel syndrome has been reported in the published literature. However, the evidence in this area remains preliminary: the available trial was small and methodologically limited, and no subsequent large, high-quality RCTs have confirmed efficacy in this population.
Serratiopeptidase is widely used in treating fibrocystic breast disease. The available data include small clinical trials but, as noted in systematic reviews, the methodological quality is low and the evidence cannot be considered definitive.
Serratiopeptidase can potentially increase the effectiveness of antibacterial therapy when used with penicillins, cephalosporins, fluoroquinolones, and tetracyclines. Researchers are focusing more on combination therapy to enhance the anti-inflammatory activity of serratiopeptidase. Vancomycin and rifampicin, combined with enzymatic agents such as serratiopeptidase, dispersin B, alpha-amylase, V8 protease, and lysostaphin, showed ample action against biofilms formed by methicillin-resistant and susceptible strains of S. aureus. The efficiency and synergistic action of anti-biofilm agents and serratiopeptidase was improved when combined with dispersal agents. Most of this evidence is derived from in vitro and animal models; robust human clinical trial data specifically on serratiopeptidase as an antibiotic adjuvant are not yet available.
Some anecdotal reports suggest serratiopeptidase possesses anti-atherosclerotic effects due to its fibrinolytic and caseinolytic properties. The evidence showing its anti-atherosclerotic effects is only anecdotal. Serratiopeptidase has been widely used for its anti-inflammatory effects, and researchers have investigated it as a potential drug candidate for vascular inflammation in cardiovascular disorder conditions. This work, however, remains at the experimental stage.
Short-term evaluation indicates that oral enzymes may be considered an effective and safe alternative to NSAIDs such as diclofenac in the treatment of painful gonarthritis. As with other indications, this evidence is based on a small number of trials with limited follow-up periods, and has not been confirmed in large, long-term studies.
Systematic reviews up to 2025 indicate modest anti-inflammatory benefits of serratiopeptidase but highlight insufficient evidence for its broad use as an analgesic. There is a dire need for conducting well-designed clinical trial-based studies for a wider spectrum of conditions, and for limiting use of serratiopeptidase until its benefits and/or contraindications are substantially proven. Among the RCTs included in systematic reviews, which were generally said to be of poor methodological quality, five studies were described as double-blind: one was completely uninterpretable, three methodologically weak studies were positive, and one trial of apparent high quality was negative.
Serratiopeptidase is given at a dose of 5–10 mg three times a day in conventional formulations. The usual doses in a majority of human studies range from 10 to 60 mg/day in divided doses, with the most preferred dose of 10 mg, thrice daily on an empty stomach. Usually, it is used for 2–4 weeks depending on the aim of therapy and outcome.
Serratiopeptidase 10 mg is equal to 20,000 units of enzyme activity. Activity-based dosing is the more precise approach, since mass-per-dose alone does not capture differences in enzyme potency across formulations. Variations in measurement units (e.g., proteolytic units per milligram) and formulation stability across production methods complicate consistent quality assurance and international pharmacopeial alignment.
Specific dosages reported in published clinical studies include:
The most common problem associated with serratiopeptidase oral delivery is the high risk of enzymatic degradation in the gastrointestinal tract due to its proteinaceous nature. In addition, the hydrophilic nature of serratiopeptidase leads to low intestinal membrane permeability, due to which a very high dosage needs to be orally administered to elicit significant anti-inflammatory responses. Oral tablet dosage forms with enteric coating and combination with controlled and sustained release properties could be an effective way to decrease the frequency of dosing and increase the bioavailability of serratiopeptidase.
Serrapeptase was well tolerated in short-term clinical trials, but long-term safety has not been evaluated. Rare, serious adverse effects reported with serrapeptase include eosinophilic pneumonitis, bullous pemphigoid, hemorrhage in a patient with Behçet disease, and possibly Stevens-Johnson syndrome.
Serrapeptase was well tolerated in short-term clinical trials enrolling more than 1,400 patients, with an incidence of adverse effects similar to that with placebo. Hypersensitivity reactions and gastric pain have been reported. With treatment lasting only 1 to 2 weeks, these studies do not provide long-term safety data for serrapeptase. In Japan, at least 4 cases of eosinophilic pneumonia have been reported with serrapeptase. Single case reports of serious adverse effects associated with serrapeptase include bullous pemphigoid, hemorrhage in a patient with Behçet disease, and Stevens-Johnson syndrome. The case of Stevens-Johnson syndrome occurred with a combination product containing serrapeptase and diclofenac, an NSAID reported to cause Stevens-Johnson syndrome.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions which are frequently caused by exposure to drugs. A careful literature search revealed that only a few reports of diclofenac-induced and one case of serratiopeptidase-associated SJS or TEN had been published. One case described a 62-year-old woman who developed a diffuse, erythematous rash on her face, trunk, and both extremities, which later turned into blisters following five days of treatment with a diclofenac and serratiopeptidase combination, with extensive ulceration of buccal, genital, and ocular mucosa. The causative role of serratiopeptidase specifically, versus the co-administered diclofenac, was not definitively established in this case.
Adverse drug reactions include allergic skin reactions which could range from dermatitis to extreme cases of Stevens–Johnson syndrome or erythema multiforme, muscle aches and joint pains, gastric disturbances like anorexia, nausea, and abdominal upset, and cough, rarely pneumonitis.
There are no clinical studies reporting any drug interactions. The only available information is from drug company monographs. Despite this absence of direct clinical interaction data, pharmacodynamic interactions are considered plausible based on mechanism:
Serrapeptase was well tolerated in short-term clinical trials, but long-term safety has not been evaluated. The available clinical trial data derive largely from studies of 1–4 weeks' duration, leaving no basis for assessing safety with prolonged use. Bleeding risk considerations apply particularly to individuals with coagulopathy, Behçet disease, or those taking concurrent anticoagulant or antiplatelet medications, as documented case reports of hemorrhage exist in this context. Serratiopeptidase is generally considered safe and effective and devoid of the side effects that commonly develop with the use of conventional mucolytics, such as sedation, euphoria, gastrointestinal disturbances, respiratory irritation, and constipation, probably due to the absence of any interaction with receptors.
Though serratiopeptidase is widely used in clinical practice around the globe, its regulatory status varies in different countries. The marketing and use of this molecule in any intended country requires approval by the designated regulatory body. Background administrative, chemistry, pre-clinical, and clinical data are needed for approval, where quality, efficacy, and safety are important parameters to be considered.
Efforts toward global regulatory harmonization are hindered by challenges in standardizing serratiopeptidase's enzyme activity, as variations in measurement units (e.g., proteolytic units per milligram) and formulation stability across production methods complicate consistent quality assurance and international pharmacopeial alignment.
Serratiopeptidase has significant potential in the treatment of conditions and diseases associated with the development of low-intensity chronic inflammation and pain syndromes due to its anti-inflammatory, anti-edematous, antithrombotic, and analgesic properties. However, the current evidentiary base is limited by small trial sizes, short durations, and heterogeneous methodology, and larger, well-designed trials are necessary before the clinical benefit can be considered established across most indications.
Health conditions that Serratiopeptidase may help support.
Serratiopeptidase (Serrapeptase), a proteolytic enzyme from Serratia marcescens, has anti-inflammatory and fibrinolytic properties that help reduce swelling, pain, and post-surgical complications in anorectal conditions. It is listed in authoritative Ayurvedic and evidence-based databases as a supportive ingredient for anal fissure and fistula management, particularly postoperatively.
Serratiopeptidase has been proposed as anti-atherosclerotic based on its fibrinolytic and proteolytic ability to degrade fibrin, cholesterol deposits, and cellular waste in arterial walls. A 2023 PMC study demonstrated vascular anti-inflammatory effects in mice. However, the Bhagat 2013 systematic review explicitly noted anti-atherosclerotic evidence is lacking in humans, classifying arterial health claims as predominantly anecdotal.
Serratiopeptidase has been studied and clinically used for both osteoarthritis and rheumatoid arthritis as an anti-inflammatory and analgesic adjunct. Clinical reviews and research summaries consistently list arthritis as an established indication. A pilot study (Klein and Kullich, 2000) examined SRP in arthritis patients. Evidence is based on small trials and is of modest quality overall.
Serratiopeptidase is clinically indicated and prescribed for back pain in India, and is listed across multiple clinical references as an indicated condition. However, the Bhagat 2013 systematic review noted no dedicated studies on back pain were found, and the Wikipedia assessment confirms no randomized evidence specifically for back pain exists. Use is based on extrapolation from its anti-inflammatory/analgesic properties.
Serratiopeptidase exhibits fibrinolytic activity documented in vitro (96.6% blood clot lysis at 300 U/mL after 4 hours at 37°C) and has been used clinically for thrombophlebitis (venous inflammatory disease with clot formation). A clinical study comparing SRP with seaprose S in venous inflammatory disease found 65% efficacy for SRP. However, no human RCT specifically for blood clot prevention has been identified.
Serratiopeptidase has been studied specifically for breast engorgement in breastfeeding/postpartum women. A double-blind RCT (Kee et al., Singapore Medical Journal, 1989, n=70) found 85.7% of SRP-treated patients had moderate-to-marked improvement in breast pain, swelling, and induration vs. 60% on placebo (P<0.05). A Cochrane database review also identified it as improving engorgement symptoms.
Serratiopeptidase has clinical evidence for supporting bronchial health through its combined mucolytic and anti-inflammatory properties. It reduces sputum viscosity and elasticity in chronic airway disease (Nakamura et al., 2003) and inhibits elastase-driven bronchial injury. Clinical use in bronchial conditions has been documented in Japan and Europe for over 40 years.
Serratiopeptidase has been clinically studied for bronchitis and chronic airway disease, with evidence for reducing sputum viscosity, elasticity, and neutrophil count. A 2003 randomized open-label trial (Nakamura et al., Respirology, n=29) found 30 mg/day for 4 weeks decreased sputum weight, viscosity, and elasticity versus no treatment. It has been used clinically for bronchitis in Japan and Europe for decades.
Serratiopeptidase (serrapeptase), a proteolytic enzyme derived from Serratia marcescens, was tested in a preliminary clinical trial of 20 CTS patients given 10 mg twice daily for 6 weeks; 65% showed significant clinical and electrophysiological improvement. It is recognized in clinical literature as a potential conservative treatment for CTS.
Serratiopeptidase has been studied across multiple clinical specialties for its anti-inflammatory effects, including reducing inflammatory cytokines and adhesion molecules. A 2013 systematic review (Bhagat et al., Int J Surg) identified 14 RCTs covering inflammatory conditions. Evidence quality is generally rated poor to moderate, with small sample sizes, but a consistent direction of benefit is reported. It has been in clinical use in Japan and Europe for ~40 years for this purpose.
Serratiopeptidase has been clinically used for chronic pain across multiple specialties including orthopedics, dentistry, and otolaryngology. Its analgesic mechanism involves hydrolysis of bradykinin, histamine, and serotonin—pain-signaling mediators. While multiple RCTs show anti-inflammatory and anti-edemic benefits, the analgesic evidence specifically is less robust, with the 2013 Bhagat systematic review noting insufficient evidence for pure analgesic efficacy.
Serratiopeptidase's fibrinolytic and anti-inflammatory properties have been proposed to support circulation by degrading intravascular fibrin deposits, reducing vascular inflammation, and improving microcirculation in edematous tissue. A 2023 PMC mouse model study demonstrated SRP attenuates LPS-induced vascular inflammation. Clinical evidence for circulation specifically is indirect, embedded within anti-edemic and fibrinolytic data.
Serratiopeptidase supports connective tissue health by selectively degrading non-viable fibrinous deposits, reducing inflammation within connective tissue compartments, and enhancing antibiotic penetration at sites of connective tissue infection. Clinical applications include carpal tunnel syndrome, osteoarticular infection, traumatic ligament injury, and post-surgical fibrous adhesion reduction.
Serratiopeptidase is listed in clinical prescribing references as an indicated agent for fibromyalgia, based on its anti-inflammatory and analgesic mechanisms. It is included among SRP clinical applications in the AJPCR review and RxList. However, no dedicated fibromyalgia RCT has been identified in the peer-reviewed literature; evidence is based on indication listings and mechanistic extrapolation from anti-inflammatory data.
Serratiopeptidase is the same enzyme as serrapeptase—a serine protease with anti-inflammatory and anti-edematous properties relevant to joint conditions. Clinical RCTs demonstrate it reduces joint swelling, stiffness, and pain while improving range of motion in musculoskeletal conditions. It is approved in several countries for inflammatory joint conditions and trauma-related mobility limitation.
Serratiopeptidase has been studied and applied in dentistry for periodontitis, pericoronitis, and post-extraction inflammation. It is used as an anti-inflammatory agent to increase antibiotic tissue penetration at periodontal infection sites. A 2014 study examined ciprofloxacin-serratiopeptidase periodontal solutions for extended drug delivery at gum sites. Multiple dental RCTs document anti-inflammatory benefits post-extraction.
Serratiopeptidase is listed in clinical prescribing references and the AJPCR clinical applications review as indicated for migraine headache and tension headache. Its proposed mechanism involves reduction of inflammatory prostaglandins and bradykinin. However, no dedicated RCTs specifically for headache have been identified in the peer-reviewed literature; use is based on clinical indication listings and anti-inflammatory mechanism extrapolation.
Serratiopeptidase has been promoted for heart health based on its fibrinolytic and anti-atherosclerotic properties—the premise being that it could reduce fibrinous and lipid deposits in coronary arteries. A 2023 PMC preclinical study showed vascular anti-inflammatory effects. However, the Bhagat 2013 systematic review found no human RCTs for cardiovascular endpoints and concluded this evidence is insufficient.
Serratiopeptidase has been proposed to enhance lymphatic drainage by degrading fibrinous deposits and reducing interstitial protein accumulation that impedes lymphatic flow. The 2024 ankle sprain study specifically attributed part of SRP's anti-edemic effect to enhancement of lymphatic drainage and facilitation of fibrinolysis. This is mechanistically plausible and cited in peer-reviewed context, though dedicated lymphatic drainage RCTs are lacking.
Serratiopeptidase supports lymphatic health by reducing interstitial fibrin and proteinaceous deposits that can impair lymphatic function, and by modulating the inflammatory responses that cause lymphatic overload. Clinical anti-edemic evidence across multiple RCTs indirectly supports lymphatic health benefits. The fibrinolytic property—dissolution of fibrin—has direct relevance to maintaining patent lymphatic channels.
Serratiopeptidase has documented use for inflammatory breast conditions including mastitis and breast engorgement. Clinical evidence (Kee et al. RCT, 1989; ScienceDirect review) shows significant reduction in breast pain, swelling, and induration in postpartum breast engorgement. SRP has been listed among therapeutic agents for fibrocystic breast disease and breast inflammation in clinical literature.
Serratiopeptidase is listed in clinical prescribing references as indicated for migraine headache, based on its anti-prostaglandin and bradykinin-hydrolyzing mechanisms. The AJPCR clinical applications review and multiple prescribing databases cite migraine as an SRP indication. No dedicated migraine RCT has been identified; evidence is based on clinical indication listings and anti-inflammatory mechanism overlap.
Serratiopeptidase acts as a mucolytic by breaking down the protein substructures of mucus, reducing its viscosity and making it easier to expectorate. Clinical trials in chronic sinusitis and chronic airway disease demonstrate significant reductions in mucus viscosity and sputum weight. It is one of the most consistently supported applications across the clinical literature.
Serratiopeptidase has documented clinical use for sports-related muscular swelling and trauma recovery. Its anti-inflammatory and anti-edemic properties accelerate the resolution of post-exercise or post-injury muscle inflammation. The Bhagat 2013 systematic review lists traumatic swelling after sports injury as an RCT-supported orthopedic indication. PMC reviews confirm its use for sports-related chronic muscular swelling.
Serratiopeptidase is clinically used for muscle pain and soreness associated with inflammation and trauma, supported by its mechanism of hydrolyzing pain-mediating molecules (bradykinin, histamine, serotonin) and reducing prostaglandin production. Clinical reviews list muscle pains among its applications. Evidence is mechanistically grounded but lacks dedicated muscle-soreness RCTs.
Multiple RCTs demonstrate serratiopeptidase reduces postoperative swelling and trismus following surgery, most consistently studied after mandibular third molar extraction. A 133-patient double-blind RCT (BMC Oral Health, 2021) showed significant reductions in trismus and swelling vs. placebo at day 4 (P<0.001). A meta-analysis of five human trials by Sivaramakrishnan and Sridharan also confirmed anti-edemic benefit. Analgesic effects are less consistent across trials.
Serratiopeptidase is the enzyme form of serrapeptase, explicitly tested in the 2021 RCT (PMC8472462) for post-COVID fatigue resolution showing significant improvement in fatigue and inflammatory markers. It has fibrinolytic, anti-inflammatory, and mucolytic mechanisms directly applicable to post-viral microclot and inflammatory burden.
Serratiopeptidase has been investigated for rheumatoid arthritis (RA) as an anti-inflammatory enzyme adjunct, with clinical literature listing it as an indication and experimental work targeting macrophages in RA using SRP-containing formulations. Several clinical reviews and the Bhagat 2013 systematic review list RA among conditions for which SRP has clinical trial data, though trials are small and methodologically weak.
Serratiopeptidase is the pharmaceutical name for serrapeptase, with clinical trials demonstrating anti-inflammatory, fibrinolytic, and anti-edemic effects relevant to postoperative scar management. It degrades fibrinous proteins in scar tissue without harming surrounding healthy cells.
Serratiopeptidase's mucolytic and anti-inflammatory actions are relevant to seasonal respiratory conditions involving mucus hypersecretion and mucosal inflammation. Clinical trials in ENT disorders and chronic sinusitis support benefit for rhinitis-type symptoms including nasal obstruction and excessive secretions. No specific seasonal allergy RCTs exist; extrapolation is from sinusitis and ENT trial data.
Clinical trials have investigated serratiopeptidase for sinusitis and related nasal congestion, finding reductions in mucus viscosity and symptom severity. A prospective open-label study (Majima et al., 1988) showed SRP reduced viscosity of nasal mucus in chronic sinusitis. A multicenter double-blind placebo-controlled trial (Mazzone et al., 1990, n=193) reported significant regression of ear, nose, and throat symptoms including nasal obstruction within 3–4 days.
Serratiopeptidase has clinical evidence for reducing symptoms of sinusitis, a condition frequently involving infection-driven inflammation and mucus hypersecretion. The Mazzone et al. 1990 multicenter RCT in 193 ENT patients (including sinusitis) found significant symptom regression. SRP also exhibits anti-biofilm activity that may reduce bacterial persistence in sinus infections. Evidence quality is modest.
Early clinical research suggests serratiopeptidase can significantly reduce pain, secretions, difficulty swallowing, and fever in patients with sore throat and acute ENT conditions. The Mazzone et al. 1990 multicenter RCT (n=193 ENT patients) reported improvements in pain severity and difficulty swallowing after 3–4 days. Evidence quality is modest but clinically documented.
Serratiopeptidase has been studied for traumatic swelling and inflammation associated with sports injuries and sprains. The 2013 Bhagat systematic review listed traumatic swelling after sports injury among orthopaedic indications supported by clinical data. A 2024 prospective comparative study (ScienceDirect) found SRP reduced ankle edema in sprain patients, attributed to its anti-inflammatory and fibrinolytic properties.
Serratiopeptidase has demonstrated clinical benefit across multiple upper respiratory conditions including sinusitis, laryngitis, rhinitis, and ENT inflammation in general. The 1990 Mazzone et al. multicenter RCT (n=193) documented significant symptom improvement in acute or chronic ENT pathologies. Clinical use in upper respiratory conditions has been established in Japan and Europe for decades.
Serratiopeptidase has documented anti-edemic effects across multiple clinical settings—post-surgical swelling, breast engorgement, and traumatic swelling after sports injury. The enzyme reduces tissue fluid accumulation by degrading fibrinous deposits and improving microcirculation/lymphatic drainage. Multiple RCTs demonstrate significant reductions in measurable edema/swelling versus placebo.
Serratiopeptidase is proposed to support wound healing by thinning inflammatory exudate fluids, facilitating drainage, and reducing swelling and pain that impede tissue repair. Multiple clinical reviews describe these mechanisms. A prospective trial referenced in the Jadhav 2020 PMC review and ResearchGate systematic review summary document enhanced drainage and wound resolution with SRP use.
Body systems that Serratiopeptidase may help support.
Go back